2m 2m 2m 2m 2m 2m 2m
- $704.2MMarket Cap
- N/A1-Year Change
- Medical Care FacilitiesIndustry
Starling Oncol (STLN)
Key Performance
More- Earnings Score: N/A
- Momentum Score: N/A
- True Yield: N/A
- Financial Health Score: N/A
Latest Research & News
The Oncology Institute Announces First Quarter 2026 Earnings Release Date and Conference Call
The Oncology Institute, Inc. (NASDAQ: TOI) announced it will release its first quarter 2026 financial results on May 7, 2026, followed by a conference call at 5:30 p.m. ET. The company also recently achieved $1.8 million in Medicare savings in the CMS Enhancing Oncology Model Performance Period 3, marking significant period-over-period improvement.
04/27/2026, 9:00 AM • GlobeNewswire
U.S. Neurology Associates Partners with M33 Growth to Transform Neurological Care
M33 Growth, a Boston-based venture firm, announced a partnership with U.S. Neurology Associates (USNA), a physician services organization focused on community-based neurology care. Nitin Jain will serve as CEO and Brad Hively as Chairman. USNA aims to provide comprehensive, integrated neurological care including in-office infusions, diagnostics, and clinical trials while reducing operational burdens on physicians and delivering cost-effective solutions to patients and payers.
01/09/2026, 4:45 PM • GlobeNewswire
The Oncology Institute Announces Leadership Promotions
The Oncology Institute promoted Rakesh Panda to Chief Information Officer and Nolan Mariano to Chief People Officer. Panda brings 25+ years of IT and digital transformation experience from roles at Cisco and Infosys, while Mariano brings 18 years of People Operations experience. The promotions support TOI's growth in value-based cancer care and technology-enabled care delivery.
01/09/2026, 8:00 AM • GlobeNewswire
The Oncology Institute (TOI) has seen a massive stock rally of over 950% in 2025, driven by its value-based cancer care approach, AI-driven operational efficiencies, and potential for growth across multiple states.
11/21/2025, 5:20 AM • The Motley Fool
Oncology Institute Sales Jump 22 Percent
The Oncology Institute reported Q2 2025 revenue of $119.8 million, a 21.5% year-over-year increase, driven by strong pharmacy segment performance. Despite revenue growth, the company continues to face challenges with net losses and cash burn.
08/13/2025, 7:06 PM • The Motley Fool
Peers
No data found
Statistics
MoreInformation as of 10/22/2026
Company Profile
Starling Oncology, Inc., an oncology company, provides various oncology services in the United States. It operates through three segments: Specialty pharmacy, Patient Services, and Clinical Trials & Other. The company offers physician services, in-house infusion, in-house specialty pharmacy, clinical trials, radiation therapy, and outpatient blood product transfusion services, as well as educational seminars, support groups, counseling services, and 24/7 patient assistance and support services. It also manages clinical trials and palliative care programs; operates combined community clinics and infusion suites; and operates a specialty pharmacy that includes both in-office and mail-order dispensing for complementary oral and self-injectable medications taken by patients concurrent with their in-office cancer therapies. It serves adult and senior cancer patients. The company was formerly known as The Oncology Institute, Inc. and changed its name to Starling Oncology, Inc. in August 2026. Starling Oncology, Inc. was founded in 2007 and is headquartered in Cerritos, California.
Key Executives
- Daniel Virnich FACHE
- Yale D. Podnos
- Robert Carter
- Minh Merchant
- Stephen Cella
Current Ownership Distribution
- Other70.9M (70.92%)
- Mutual Funds18.0M (18.01%)
- Insiders11.1M (11.07%)
- Institutions0 (0.00%)